ABVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abivax SA (ABVX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has a bullish technical setup, positive analyst sentiment, and strong potential catalysts in its pipeline, particularly in Crohn's disease and ulcerative colitis. The SwingMax signal further supports a buy decision.
The stock shows a bullish trend with SMA_5 > SMA_20 > SMA_200. MACD is above 0 and positively contracting, indicating upward momentum. RSI is neutral at 55.346, suggesting no overbought or oversold conditions. Key support and resistance levels are Pivot: 120.679, R1: 126.951, and S1: 114.407.
and Jefferies ($
reflect confidence in the company's growth potential. The upcoming Q2 maintenance readout is viewed as de-risked and could act as a significant catalyst.
Wedbush has an Underperform rating with a $110 price target, citing caution around M&A rumors and potential downside if Q2 data or deals fail to materialize.
No financial data available for analysis.
The majority of analysts are bullish, with recent upgrades and price target increases from Oddo BHF, Barclays, and Jefferies. However, Wedbush remains bearish with an Underperform rating.
